Efficacy and safety of Siponimod in SPMS

So  here we have it an drug with an effect on SPMS that slows progression in a phase III trial So this is good news.
The bad news I guess, is that the drug only slowed the rate of 3 month progression by 22% over so disease was not halted and an effect on 25 foot walking was not apparent and at the end of the study about 18% decided to withdraw which must mean that they were dissatisfied with the outcome.

Read More  – Click Here


BartsMS HeaderThe aim of this Blog is for the Barts and The London Neuroimmunology Group to update you on the latest research in MS with an emphasis on the research we are involved in. A major reason for maintaining the Blog is to thank the funders of our research. Funders encourage us to engage with the general public, people with MS and their families and other people with an interest in MS.  We believe you have the right to know what we are spending your research money on! The purpose of our work is to improve our knowledge and understanding of MS with the goal of improving the lives of people living with this disease.

Website: http://multiple-sclerosis-research.blogspot.com/


MS Unites is proud to have been approved by Barts MS to bring multiple sclerosis research & news to our global readership.